Business Context and Reporting Period
This Form 8-K filing by eXegenics Inc. (not OPKO Health, Inc.) reports a material change in control and corporate governance events occurring on February 8 and February 9, 2007. The filing details the consummation of a private stock sale approved by stockholders at a special meeting.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data relates to the capital raise transaction:
- Total Shares Sold: 19,440,491 shares of common stock.
- Aggregate Purchase Price: $8,613,000 (subject to adjustment based on stockholders' equity at closing).
- Payment Method: Wire transfer in immediately available funds.
- Outstanding Capital: As of February 9, 2007, there were 36,531,592 shares of common stock and 1,002,017 shares of Series A preferred stock outstanding.
Material Changes Versus Prior Period
The filing reports a significant shift in ownership and control:
- Change in Control: The Investors (led by The Frost Group, LLC and New Valley, LLC) now own approximately 51% of eXegenics common stock on a fully diluted basis, representing 51% of the voting power.
- Board Composition: Robert Benou and David Lee Spencer resigned from the board. Steven D. Rubin, Jane Hsiao, and Subbarao Uppaluri were elected as new directors.
- Authorized Capital: The certificate of incorporation was amended to increase authorized common shares from 30,000,000 to 225,000,000.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future business operations. Key governance and contingency details include:
- Voting Agreements: Investors have entered into a three-year voting agreement to elect John Paganelli and Robert Baron as directors.
- Executive Compensation: 50,000 shares of common stock were granted to CEO John A. Paganelli and Director Robert Baron for services to the business opportunities search committee, contingent on stockholder approval.
- Regulatory Status: The stock sale was conducted under exemptions from registration (Section 4(2) and Rule 506 of the Securities Act of 1933).
Important Facts for Investor Verification
- Verify the final adjusted purchase price, as the initial $8,613,000 was subject to adjustment based on equity at closing.
- Confirm the specific terms of the voting agreements and the duration of the new directors' tenure.
- Review the impact of the 51% ownership change on future strategic direction and potential conflicts of interest.
- Check subsequent filings for the actual number of shares issued after the equity adjustment calculation.